French drug maker Sanofi-aventis says that results from a Phase III trial of its experimental type 2 diabetes drug lixisenatide show that the drug successfully lowered patients' blood glucose levels and body weight, but did not increase the risk of hypoglycemia.
Albertson's LLC, a nationwide supermarket chain with more than 200 stores, has announced that it will participate in the Diabetes Control Program (DCP) of the Diabetes Prevention and Control Alliance. The DCP works through trained pharmacists to provide education and support to people with diabetes.
The Chicago Athenaeum: Museum of Architecture has announced its 60th annual Good Design Awards, which honor "quality design of the highest form, function, and aesthetic." Guess which paragon of contemporary design won an award this year? An insulin needle. Called the NovoTwist and made by Novo Nordisk for use with insulin pens, this marvel of design has a bayonet fitting that allows "just twist" attachment and detachment to compatible pens, and an audible and tactile "click" that confirms attachment of the needle.
RALEIGH, NC- DiabetesSisters is pleased to announce that registration for the 2011 Weekend for Women Conference in Raleigh, NC will open on January 1, 2011 at 8am. The Conference, a revolutionary national weekend conference designed specifically for women with diabetes, will take place April 29 - May 1, 2011 at the Marriott City Center in downtown Raleigh.
Novo Nordisk, a world leader in diabetes care, has partnered with Chip Ganassi Racing, LLC to create the Novo Nordisk Chip Ganassi Racing team for the 2011 IZOD IndyCar season. The team will sponsor a new entry in the series driven by American racecar driver Charlie Kimball. This partnership makes Kimball one of the first drivers from the 2010 Firestone Indy Lights series to move up the official "Road to Indy" with a full season sponsorship.
Calibra Medical has announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its FinesseTM insulin patch-pen for up to three-day use with Novo Nordisk's Novolog® rapid-acting insulin. This much-anticipated step closer to market release follows the announcement in January that Calibra received FDA clearance for the device for use with Eli Lilly's Humalog® rapid-acting insulin.
Novo Nordisk announced today the availability of NovoDoseTM - the first-ever mobile insulin dosing guide for physicians to look up dosing guidelines and blood glucose goals for their patients with diabetes, a disease that affects nearly 24 million Americans. The guide is available as an application on iTunes and is specific to Novo Nordisk's modern insulin analog portfolio: Levemir® (insulin detemir [rDNA origin] injection), NovoLog® (insulin aspart [rDNA origin] injection), and NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]).
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.